Led by $1bn acquisition of MediFox DAN Group, Europe’s medical devices industry saw a rise of 11.93% in deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 129 deals worth $3.7bn were announced for the region during Q2 2022, against the last four-quarter average of 115.25 deals.

Of all the deal types, venture financing saw most activity in Q2 2022 with 64 deals, representing a 49.6% share for the region.

In second place was M&A with 48 deals, followed by private equity deals with 17 transactions, respectively capturing a 37.2% and 13.2% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $2.2bn, while private equity and venture financing deals totalled $902.46m and $569.04m, respectively.

Europe medical devices industry deals in Q2 2022: Top deals

The top five medical devices deals accounted for a 71.3% share of the overall value during Q2 2022.

The combined value of the top five deals stood at $2.62bn, against the overall value of $3.7bn recorded for the quarter.

1) ResMed $1bn acquisition deal with MediFox DAN Group

2) The $797.86m private equity of SPT Labtech by EQT IX Fund

3) Wallaby Medical $541.63m acquisition deal with Phenox

4) The $141.73m acquisition of Aran Biomedical by Integer

5) Straumann $138.06m acquisition deal with SunshineSmile